Literature DB >> 28119481

Lacosamide Inhibition of Nav1.7 Voltage-Gated Sodium Channels: Slow Binding to Fast-Inactivated States.

Sooyeon Jo1, Bruce P Bean2.   

Abstract

Lacosamide is an antiseizure agent that targets voltage-dependent sodium channels. Previous experiments have suggested that lacosamide is unusual in binding selectively to the slow-inactivated state of sodium channels, in contrast to drugs like carbamazepine and phenytoin, which bind tightly to fast-inactivated states. Using heterologously expressed human Nav1.7 sodium channels, we examined the state-dependent effects of lacosamide. Lacosamide induced a reversible shift in the voltage dependence of fast inactivation studied with 100-millisecond prepulses, suggesting binding to fast-inactivated states. Using steady holding potentials, lacosamide block was very weak at -120 mV (3% inhibition by 100 µM lacosamide) but greatly enhanced at -80 mV (43% inhibition by 100 µM lacosamide), where there is partial fast inactivation but little or no slow inactivation. During long depolarizations, lacosamide slowly (over seconds) put channels into states that recovered availability slowly (hundreds of milliseconds) at -120 mV. This resembles enhancement of slow inactivation, but the effect was much more pronounced at -40 mV, where fast inactivation is complete, but slow inactivation is not, than at 0 mV, where slow inactivation is maximal, more consistent with slow binding to fast-inactivated states than selective binding to slow-inactivated states. Furthermore, inhibition by lacosamide was greatly reduced by pretreatment with 300 µM lidocaine or 300 µM carbamazepine, suggesting that lacosamide, lidocaine, and carbamazepine all bind to the same site. The results suggest that lacosamide binds to fast-inactivated states in a manner similar to other antiseizure agents but with slower kinetics of binding and unbinding.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28119481      PMCID: PMC5363714          DOI: 10.1124/mol.116.106401

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  43 in total

1.  Role of amino acid residues in transmembrane segments IS6 and IIS6 of the Na+ channel alpha subunit in voltage-dependent gating and drug block.

Authors:  Vladimir Yarov-Yarovoy; Jancy C McPhee; Diane Idsvoog; Caroline Pate; Todd Scheuer; William A Catterall
Journal:  J Biol Chem       Date:  2002-07-18       Impact factor: 5.157

2.  Amino acid residues required for fast Na(+)-channel inactivation: charge neutralizations and deletions in the III-IV linker.

Authors:  D E Patton; J W West; W A Catterall; A L Goldin
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

3.  Structural parts involved in activation and inactivation of the sodium channel.

Authors:  W Stühmer; F Conti; H Suzuki; X D Wang; M Noda; N Yahagi; H Kubo; S Numa
Journal:  Nature       Date:  1989-06-22       Impact factor: 49.962

Review 4.  Structural Basis for Pharmacology of Voltage-Gated Sodium and Calcium Channels.

Authors:  William A Catterall; Teresa M Swanson
Journal:  Mol Pharmacol       Date:  2015-04-06       Impact factor: 4.436

5.  Modulation of neuronal sodium channels by the sea anemone peptide BDS-I.

Authors:  Pin Liu; Sooyeon Jo; Bruce P Bean
Journal:  J Neurophysiol       Date:  2012-03-21       Impact factor: 2.714

6.  Lidocaine, carbamazepine, and imipramine have partially overlapping binding sites and additive inhibitory effect on neuronal Na+ channels.

Authors:  Ya-Chin Yang; Chen-Syuan Huang; Chung-Chin Kuo
Journal:  Anesthesiology       Date:  2010-07       Impact factor: 7.892

7.  Lidocaine reduces the transition to slow inactivation in Na(v)1.7 voltage-gated sodium channels.

Authors:  Patrick L Sheets; Brian W Jarecki; Theodore R Cummins
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

8.  Development and characterization of novel derivatives of the antiepileptic drug lacosamide that exhibit far greater enhancement in slow inactivation of voltage-gated sodium channels.

Authors:  Yuying Wang; Ki Duk Park; Christophe Salome; Sarah M Wilson; James P Stables; Rihe Liu; Rajesh Khanna; Harold Kohn
Journal:  ACS Chem Neurosci       Date:  2011-02-16       Impact factor: 4.418

Review 9.  Lacosamide: in partial-onset seizures.

Authors:  Sarah A Cross; Monique P Curran
Journal:  Drugs       Date:  2009       Impact factor: 9.546

10.  The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels.

Authors:  Adam C Errington; Thomas Stöhr; Cara Heers; George Lees
Journal:  Mol Pharmacol       Date:  2007-10-16       Impact factor: 4.436

View more
  10 in total

1.  Impaired chromaffin cell excitability and exocytosis in autistic Timothy syndrome TS2-neo mouse rescued by L-type calcium channel blockers.

Authors:  Chiara Calorio; Daniela Gavello; Laura Guarina; Chiara Salio; Marco Sassoè-Pognetto; Chiara Riganti; Federico Tommaso Bianchi; Nadja T Hofer; Petronel Tuluc; Gerald J Obermair; Paola Defilippi; Fiorella Balzac; Emilia Turco; Glenna C Bett; Randall L Rasmusson; Emilio Carbone
Journal:  J Physiol       Date:  2019-01-28       Impact factor: 5.182

Review 2.  Modulation of sodium channels as pharmacological tool for pain therapy-highlights and gaps.

Authors:  Nilufar Foadi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-03-23       Impact factor: 3.000

3.  Enhancing inactivation rather than reducing activation of Nav1.7 channels by a clinically effective analgesic CNV1014802.

Authors:  Yue-Ming Zheng; Wan-Fu Wang; Yan-Fen Li; Yong Yu; Zhao-Bing Gao
Journal:  Acta Pharmacol Sin       Date:  2017-11-02       Impact factor: 6.150

4.  Mutations in SCN3A cause early infantile epileptic encephalopathy.

Authors:  Tariq Zaman; Ingo Helbig; Ivana Babić Božović; Suzanne D DeBrosse; A Christina Bergqvist; Kimberly Wallis; Livija Medne; Aleš Maver; Borut Peterlin; Katherine L Helbig; Xiaohong Zhang; Ethan M Goldberg
Journal:  Ann Neurol       Date:  2018-03-30       Impact factor: 10.422

5.  Lidocaine Binding Enhances Inhibition of Nav1.7 Channels by the Sulfonamide PF-05089771.

Authors:  Sooyeon Jo; Bruce P Bean
Journal:  Mol Pharmacol       Date:  2020-03-19       Impact factor: 4.436

Review 6.  Using stratified medicine to understand, diagnose, and treat neuropathic pain.

Authors:  Andreas C Themistocleous; Geert Crombez; Georgios Baskozos; David L Bennett
Journal:  Pain       Date:  2018-09       Impact factor: 7.926

7.  Pain relief in a neuropathy patient by lacosamide: Proof of principle of clinical translation from patient-specific iPS cell-derived nociceptors.

Authors:  Barbara Namer; Diana Schmidt; Esther Eberhardt; Michele Maroni; Eva Dorfmeister; Inge Petter Kleggetveit; Luisa Kaluza; Jannis Meents; Aaron Gerlach; Zhixin Lin; Andreas Winterpacht; Elena Dragicevic; Zacharias Kohl; Jürgen Schüttler; Ingo Kurth; Torhild Warncke; Ellen Jorum; Beate Winner; Angelika Lampert
Journal:  EBioMedicine       Date:  2018-11-28       Impact factor: 8.143

8.  Differential effect of lacosamide on Nav1.7 variants from responsive and non-responsive patients with small fibre neuropathy.

Authors:  Julie I R Labau; Mark Estacion; Brian S Tanaka; Bianca T A de Greef; Janneke G J Hoeijmakers; Margot Geerts; Monique M Gerrits; Hubert J M Smeets; Catharina G Faber; Ingemar S J Merkies; Giuseppe Lauria; Sulayman D Dib-Hajj; Stephen G Waxman
Journal:  Brain       Date:  2020-03-01       Impact factor: 13.501

9.  Lacosamide Inhibition of NaV1.7 Channels Depends on its Interaction With the Voltage Sensor Domain and the Channel Pore.

Authors:  Julie I R Labau; Matthew Alsaloum; Mark Estacion; Brian Tanaka; Fadia B Dib-Hajj; Giuseppe Lauria; Hubert J M Smeets; Catharina G Faber; Sulayman Dib-Hajj; Stephen G Waxman
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

Review 10.  Peripheral Voltage-Gated Cation Channels in Neuropathic Pain and Their Potential as Therapeutic Targets.

Authors:  Sascha R A Alles; Peter A Smith
Journal:  Front Pain Res (Lausanne)       Date:  2021-12-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.